Retrospective Multicenter Observational Study to Evaluate Safety and Effectiveness of Bevacizumab (Avastin) in Combination With Paclitaxel and Cisplatin/Carboplatin or Toptecan in Patients With Advanced Cervical Cancer

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 19 Mar 2018

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Topotecan
Indications Cervical cancer
Focus Adverse reactions
Sponsors Roche

Most Recent Events

28 Feb 2018 Status changed from recruiting to completed.
29 Sep 2017 Planned End Date changed from 1 Sep 2017 to 20 Oct 2017.
29 Sep 2017 Planned primary completion date changed from 1 Jul 2017 to 20 Oct 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight